Form 4: Regulus Therapeutics Director Stelios Papadopoulos Acquires 250,000 Shares

Director Stelios Papadopoulos of Regulus Therapeutics Inc. reports acquiring 250,000 shares of common stock at $1.60 per share on March 14, 2024.

Summary

• On March 14, 2024, Stelios Papadopoulos, a director of Regulus Therapeutics Inc., acquired 250,000 shares of common stock.
• The shares were purchased at a price of $1.60 per share.
• This transaction increased Papadopoulos's total holdings to 978,388 shares.
• The acquisition was made under a Securities Purchase Agreement dated March 11, 2024, which was approved by the Issuer's Board of Directors and an independent committee thereof.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. The purchase itself could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• A director's increased investment in the company may signal confidence in its future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding 10% or more of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors as they can provide insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The acquisition of shares by a director could potentially increase investor confidence.

Key Dates